The Leukemia & Lymphoma Society (LLS) Therapy Acceleration Program (TAP)
Overview
The Leukemia & Lymphoma Society's Therapy Acceleration Program (LLS TAP) is a strategic venture philanthropy initiative that seeks to accelerate the development of innovative blood cancer therapeutics and change the standard of care. LLS TAP collaborates with biotech companies to support the development of novel platforms, first-in-class assets addressing unmet medical needs, emerging patient populations and even rare blood cancers. TAP funds late-stage preclinical studies, and proof of concept or registrational clinical trials to help advance therapeutics along the drug development and approval pathway. LLS TAP makes individual investments of up to approximately $10 million and offers insights to funded companies from its extensive knowledge of blood cancer indications, the treatment landscape, and the expertise of LLS staff.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Solu Therapeutics | Apr 2025 | Series A | Co-investor |
| Immunitas Therapeutics | Aug 2021 | Series B | Co-investor |
| Immune-Onc Therapeutics | Jan 2023 | Series B Extension | - |
| Enterome | Jun 2025 | VC Round | Co-investor |
| Abintus Bio | Apr 2021 | Seed | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is The Leukemia & Lymphoma Society (LLS) Therapy Acceleration Program (TAP) based?
The Leukemia & Lymphoma Society (LLS) Therapy Acceleration Program (TAP) is headquartered in Rye Brook, New York, United States.
When was The Leukemia & Lymphoma Society (LLS) Therapy Acceleration Program (TAP) founded?
The Leukemia & Lymphoma Society (LLS) Therapy Acceleration Program (TAP) was founded in 2007.
How many portfolio companies does The Leukemia & Lymphoma Society (LLS) Therapy Acceleration Program (TAP) have?
The Leukemia & Lymphoma Society (LLS) Therapy Acceleration Program (TAP) has 7 portfolio companies in Caplight's dataset.
What are some companies in The Leukemia & Lymphoma Society (LLS) Therapy Acceleration Program (TAP)'s portfolio?
Portfolio companies visible on Caplight include Solu Therapeutics, Immunitas Therapeutics, Immune-Onc Therapeutics, Enterome, Abintus Bio.
What was The Leukemia & Lymphoma Society (LLS) Therapy Acceleration Program (TAP)'s most recent investment shown here?
The Leukemia & Lymphoma Society (LLS) Therapy Acceleration Program (TAP)'s most recent investment in this portfolio sample was in Enterome in 2025.
What sectors does The Leukemia & Lymphoma Society (LLS) Therapy Acceleration Program (TAP) focus on?
The Leukemia & Lymphoma Society (LLS) Therapy Acceleration Program (TAP) focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does The Leukemia & Lymphoma Society (LLS) Therapy Acceleration Program (TAP) focus on?
The Leukemia & Lymphoma Society (LLS) Therapy Acceleration Program (TAP) typically invests at the MultiStage stage.
What is The Leukemia & Lymphoma Society (LLS) Therapy Acceleration Program (TAP)'s AUM?
The Leukemia & Lymphoma Society (LLS) Therapy Acceleration Program (TAP)'s assets under management are estimated between $100.0M and $250.0M.